Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.60 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 4/20 | 0.47 |
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MMP13 | P45452 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251968 | 0.89 | NPC1 (0.59) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL984422 | 0.88 | RAB9A (0.59) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL986022 | 0.86 | RAB9A (0.65) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL986061 | 0.85 | MMP13 (0.57) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL987534 | 0.85 | NPBWR1 (0.61) | NPC1SMN1; SMN2RAB9AMAPTMMP2 | |
| SCHEMBL987496 | 0.85 | NPBWR1 (0.61) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL984215 | 0.85 | MAPT (0.49) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL2977867 | 0.85 | NPC1 (0.43) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL984016 | 0.85 | SCN2A (0.48) | NPC1PKN1PKN2SMN1; SMN2RAB9A | |
| SCHEMBL984150 | 0.82 | NPC1 (0.63) | NPC1SMN1; SMN2RAB9AMAPTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | NPC1 3527/4885PKN1 1205/4885PKN2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.